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STEMIAbstract Background: Platelet aggregation occurs as a central role in acute coronary syndrome
(ACS), and glycoprotein GP IIb/IIIa inhibitors may enhance the beneﬁts expected from early recan-
alisation.
Aim: To compare the degree of platelet aggregation inhibition achieved by Eptiﬁbatide versus high
dose Tiroﬁban, and its clinical effects regarding myocardial reperfusion parameters: myocardial
blush grade (MBG) and ST-segment resolution (STR) >70%, and regarding peri procedural com-
plications, bleeding and major adverse cardiac events (MACE).
Methods: Between the period of June 2010–January 2012, 46 patients with acute myocardial infarc-
tion whose symptom onset is within 12 h of presentation and ECG showing ST-segment elevation
1 mm in two contiguous limb leads or 2 mm in two contiguous precordial leads or acute left bundle
branch block were included. Exclusion criteria were active bleeding, thrombocytopenia, bleeding
diathesis, anticoagulation or thrombolitics, recent major surgery or stroke, cardiogenic shock,
and pregnancy. Patients were randomized alternatively (1:1) into two groups before primary percu-
taneous cardiac intervention (PCI) to receive the speciﬁc glycoprotin IIb/IIIa inhibitor as follows:
(I) Tiroﬁban group: intravenous high bolus dose of 25 mcg/kg over 3 min followed by maintenance
infusion of 0.15 mcg/kg/min. (II) Eptiﬁbatide group: intravenous two boluses 10 min apart (each
one is 180 mcg/kg) followed by maintenance of 2 mcg/kg/min.
Platelet aggregation inhibition was measured by light transmission aggregometer, angiographic
assessment was done before and after ﬁnal interventions for TIMI ﬂow and myocardial blush grade
before and after the procedure. Electrocardiographic assessment standard 12-lead ECG on admis-
sion, immediately after PCI. Resolution of ST segment elevation was expressed as a percentage of
the initial ST segment elevation. Resolution of P70% was deﬁned as complete resolution.
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adverse cardiac events (MACE): death, non-fatal myocardial infarction (MI), and target vessel
revascularization (TVR).
Results: The total patients in our study included 46 patients, 40 males (87%) and six females (13%)
with a mean age of 55 ± 10, Tiroﬁban group: included 23 patients, 19 males (82.5%) and four
females (17.4%) with a mean age of 57 ± 9.65. Eptiﬁbatide group: included 23 patients, 21 males
(87%) and two females (8.7%) with a mean age of 53.48 ± 8.6.
Platelet aggregation inhibition during PCI was signiﬁcantly correlated with STR (p 0.013, r 0.71).
The cut-off point for platelet aggregation inhibition as a predictor of STR >70% was 89.5% (sen-
sitivity 92.3%, speciﬁcity 69.2%, PPV 75% and NPV 10%, AUC 0.87). Platelet aggregation inhi-
bition during PCI was positively correlated with MBG (p 0.045, r 0.453). The cut-off point for
platelet aggregation inhibition as a predictor of MBG 2–3 was 87.5% (sensitivity 73.6%, speciﬁcity
66.7%, PPV 93.9% and NPV 76.9%, AUC 0.81).
Platelet aggregation inhibition 60 min after bolus was (93.57 ± 2.07% versus 87.62 ± 3.2%,
p< 0.001) and 6 h later (89.85 ± 2.03% versus 78.5 ± 7.07%, p< 0.001) in Eptiﬁbatide versus
Tiroﬁban groups, respectively. Post procedural TIMI ﬂow III was (95.7% versus 91.3%, p 1), mean
MBG (2.87 ± 0.34 versus 2.09 ± 0.73, p< 0.001) and STR >70% (56.22% versus 39.13%, p
0.005) in Eptiﬁbatide versus Tiroﬁban group, respectively.
There was no signiﬁcant statistical difference regarding thrombocytopenia (46.73 ± 41.48 versus
39.04 ± 34.41, p 0.37), minor bleeding (17.4% versus 21.7%, p 0.5), major bleeding (0% versus
4.3%, p 0.5), post procedural infarction (0% versus 17.4%, p 0.12), TVR (0% versus 8.7%, p
0.24), MACE and 30 days mortality (4.3% versus 13%, p 0.34) in Eptiﬁbatide versus Tiroﬁban
group, respectively.
Conclusions:
• Platelet aggregation inhibition during PCI was signiﬁcantly correlated with STR and
MBG. Platelet aggregation inhibition cut-off point as a predictor of STR >70% was
89.5%, and as a predictor of MBG 2–3 was 87.5%.
• Eptiﬁbatide achieves better platelet aggregation inhibition 60 min after bolus and 6 h after
PCI than high dose Tiroﬁban.
• Eptiﬁbatide is associated with better myocardial perfusion as indicated by post procedural
mean MBG and STR >70% than high dose Tiroﬁban.
• There was no signiﬁcant differences between Eptiﬁbatide and high dose Tiroﬁban regard-
ing thrombocytopenia, major or minor bleeding, MACE and 30 days mortality.
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Platelet aggregation occurs as a central role of an intercon-
nected pattern of plaque disruption, lipid accumulation, mural
thrombus formation, and lesion progression in acute coronary
syndrome (ACS). When plaque rupture occurs, the subendo-
thelial protein matrix is disrupted, allowing platelet adhesion
molecules such as Von Willebrand factor and collagen to inter-
act with circulating platelets with platelet activation and
degranulation.1 Early administration of glycoprotein GP IIb/
IIIa inhibitors is more valuable for the potential beneﬁts ex-
pected from early recanalisation2,3 abciximab has been shown
to reduce mortality in patients undergoing primary angio-
plasty.4,5 Abciximab is recommended as class IIa (level of evi-
dence A), Eptiﬁbatide as class IIa (level of evidence B) while
Tiroﬁban class IIb (level of evidence B) according to the current
guidelines of the task force on myocardial revascularization of
the European Society of Cardiology (ESC) and the European
Association for Cardio-Thoracic Surgery (EACTS 2010).6
There has not been to date, to our knowledge, any large
randomized studies directly comparing Eptiﬁbatide versus
high dose Tiroﬁban as regards platelet aggregation inhibition
and myocardial reperfusion parameters in patients with ST
segment myocardial infarction (STEMI). One study (JianjinTang et al., 2008) compared both drugs regarding efﬁcacy
and safety in non-ST segment elevation ACS (UA/NSTEMI)
and concluded that Eptiﬁbatide decreases ischemic events
without signiﬁcant differences in bleeding complications.
2. Aim of the work
(1) To compare the degree of platelet aggregation inhibition
achieved by Eptiﬁbatide versus high dose Tiroﬁban.
(2) To compare the efﬁcacy of Eptiﬁbatide versus high dose
Tiroﬁban regarding myocardial reperfusion parameters:
myocardial blush grade (MBG) and ST-segment resolu-
tion (STR) >70%.
(3) Assessment of the safety of Eptiﬁbatide versus high dose
Tiroﬁban regarding peri procedural complications,
bleeding and major adverse cardiac events (MACE).
3. Patients and methods
Between the period of June 2010–January 2012, 46 patients were
admitted to the critical care department at the Cairo university
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and amenable to primary coronary intervention were enrolled
after being informed about the nature of the study and signing
a consent to participate by the responsible family member.
Inclusion criteria: All patients with acute myocardial infarc-
tion whose symptom onset is within 12 h of presentation and
ECG showing ST-segment elevation 1 mm in two contiguous
limb leads or 2 mm in two contiguous precordial leads or acute
left bundle branch block. [class I recommendation for primary
PCI according to the American College of Cardiology/Ameri-
can Heart Association (ACC/AHA) and European Society of
Cardiology (ESC) guidelines 2010].6,7
Exclusion criteria:
Æ Patients with cardiogenic shock (SBP <80 mmHg for
> 30 min or requiring pressors or IABP due to
hypotension).
Æ Patients with cardiac arrest at any point prior to interven-
tion (within the preceding 24 h).
Æ Patients on chronic warfarin (Coumadin) therapy.
Æ Patients with known bleeding diathesis or active bleeding
within prior 3 months.
Æ Patients who receive thrombolytic therapy prior to PCI
(within the preceding 8 h).
Æ Patients with a platelet count <100,000 cells/mm3 within
the preceding 7 days.
Æ Patients with major surgery within the past 6 months or
scheduled surgery within 6 weeks. Patients with signiﬁcant
unprotected left main disease (stenosis >60%) or with mul-
tivessel coronary disease that will require emergent coro-
nary artery bypass surgery.
Æ Patients with transient ischemic attack (TIA) or cerebrovas-
cular accident (CVA) within the past 30 days or any history
of hemorrhagic stroke.
Æ Patient is known to be pregnant or lactating.
3.1. Methods
Following admission all patients were subjected to the follow-
ing: Full medical history, clinical examination and labora-
tory investigations including: Random blood sugar, kidney
function tests (BUN, creatinine, Na, and K), liver function
tests (PT, PC, SGOT, and SGPT), cardiac enzymes (CK,
CK-MB, LDH, and troponin) on admission and 6 and
24 h after intervention and when needed. Hemoglobin,
hematocrit and platelets count on admission and 24 h after
procedure.
 Patients were randomized by alternation (1:1) into two
groups before intervention to receive the speciﬁc glycopro-
tein IIb/IIIa inhibitor as follows:
1. Tiroﬁban group: intravenous high bolus dose 25 lg/kg over
3 min followed by maintenance infusion 0.15 mcg/kg/min.
2. Eptiﬁbatide group: intravenous two boluses 10 min apart
(each one is 180 mcg/kg) followed by maintenance 2 mcg /
kg /min.
All patients received oral 300 mg aspirin and 600 mg clop-
idogrel on admission. Other drugs e.g. heparin, statins, nitro-
glycerin, ACEI, B-blockers, Ca-channel blockers, andantiarrhythmics were given according to standard ESC guide-
lines management of acute MI.8 Cardiac catheterization was
performed using Judkin’s catheter (six French) via right femo-
ral approach in 45 patients (97.8%) and radial approach in one
case (2.2%) in the Eptiﬁbatide group as preferred by the angi-
ographer in the absence of peripheral vascular disease. Symp-
tom to balloon time was 7.39 ± 1.6, 7.98 ± 0.95 h in the
Tiroﬁban and Eptiﬁbatide groups, respectively
(p= 0.61).Aspiration of thrombus using Diver C device was
done in two cases.
Platelet aggregation inhibition assessment: Turbidometric
platelet aggregation was done using light transmission aggre-
gometer. Aggregation was performed on CHRONO-LOG
platelet aggregometer (Chrono-Log Corporation, 2 W Park
Rd., Havertown, PA 19083-4691, USA) using ADP (at con-
centration, 20M) Blood samples were taken before the start
of GP IIb/IIIa inhibitors, 60 min after starting (during) PCI
and 6–8 h later, then anticoagulated with citrate and tested
for platelet aggregation.
Aggregation %= 100 (baseline platelet count – platelet
count after adding ADP)/baseline platelet count. Platelet
count drop = the difference between platelet count on admis-
sion and the count after 24 h.
Angiographic assessment of TIMI ﬂow and myocardial
blush grade (MBG) was done before and at the end of the
interventions.
Electrocardiographic assessment: Standard 12-lead ECG
ST-segment deviation in all leads is summed and compared be-
fore and after intervention. Resolution of ST segment eleva-
tion was expressed as a percentage of the initial ST segment
elevation.
Bleeding complications: Classiﬁed into major and minor
bleeding according to the criteria of the Thrombolysis in
Myocardial Infarction trials9 Major bleeding: hemoglobin
drop of >5 gm/dl with or without an identiﬁed site, intra-
cranial hemorrhage or cardiac tamponade. Minor bleeding:
hemoglobin drop of >3 gm/dl with bleeding from a known
site, spontaneous gross hematuria, hematemesis, or
hemoptysis.
Site access complications: A–V ﬁstula, pseudoaneurysm,
major hematoma (hematoma + 15% decrease in hematocrite
ratio) or the need for surgical repair.
Major adverse cardiac events (MACE) referred to a com-
posite of endpoints in PCI trials to describe the clinical out-
come: death, non-fatal MI, a new myocardial infarction was
deﬁned as the ﬁnding of levels of the MB isoform of creatine
kinase that were at least three times the upper limit of the nor-
mal range in two separate blood samples or by the ﬁnding of
abnormal Q waves in two or more contiguous leads and
TVR (target vessel revascularization).
3.2. Statistical analysis
Data were collected and coded prior to analysis using the pro-
fessional statistical Package for Social Science (SPSS 17). All
data were expressed as mean and standard deviation (SD).
Frequency tables for all categorical data. Student’s t-test (un-
paired) after checking normality for all continuous data. Mann
Whitney test was used when the value of standard deviation
was violated. Chi-square test for all categorical data to test
for the presence of an association. For small sample size ﬁsher
Table 1 Demographic data of Tiroﬁban and Eptiﬁbatide groups.
Characteristics Tiroﬁban group Eptiﬁbatide group p value
Age 57 ± 9.6 53.48 ± 8.6 0.19
Sex Male 19(82.6) 21(91.3%) 0.68
Female 4(17.4%)21 2(8.7%) 0.87
Diabetes mellitus 10(43.5%) 11(47.8%) 0.5
HTN 17(73.9%) 15(65.2%) 0.37
Dyslipidaemia 17(73.9%) 18(78.3%) 0.5
Smoking 19(82.6%) 21(91.3%) 0.33
Family history of IHD 18(78.3%) 11(47.8%) 0.033
BMI Normal 4(17.4%) 9(39.1%) 0.26
Mild obesity 14(60.9%) 12(52.2%) 0.84
Moderate obesity 5(21.7%) 2(8.7%) 0.45
Previous PCI 1(4.3%) 2(8.7%) 0.5
MI Anterior 13(56.5%) 9(39.1%) 0.230
Inferior 10(43.5%) 14(60.9%) 0.189
Angiographic data
Diseased vessels
Single 9(39.1%) 7(30.4%) 0.804
Two vessels 4(17.4%) 11(47.8%) 1.00
Multivessel 4(17.4%) 5(21.7%) 1.00
Infarction related artery
LAD 13(56.5%) 9(39.1%) 0.804
CX 6(26.1%) 4(17.4%) 0.824
RCA 4(17.4%) 10(43.5%) 0.427
Lesion site
Proximal 14(60.9%) 15(65.2%) 0.851
Mid segment 9(39.1%) 6(26.1%) 0.607
Distal 0(0%) 2(8.7%) 0.500
Symptom to balloon (hours) 7.39 ± 1.6 7.98 ± 0.95 0.61
Reference vessel diameter (RVD) 3.12 ± 0.43 3.20 ± 0.36 0.71
Minimal luminal diameter (MLD) 0.19 ± 0.42 0.03 ± 0.17 0.34
TIMI ﬂow pre-PCI 01
0 21(91.3%) 20(87%) 1.00
1 2 (8.7%) 3(13%) 1.00
Figure 1 platelet aggregation inhibition in Tiroﬁban and Eptiﬁbatide groups.
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Figure 2 TIMI ﬂow post PCI in Tiroﬁban and Eptiﬁbatide groups.
Figure 3 ROC curve for platelet aggregation inhibition and STR
>70%.
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signiﬁcant.Table 2 Tiroﬁban versus Eptoﬁbatide effects on Platelet aggregatio
Tiroﬁban group
Platelet aggregation inhibition
On admission 15.5 ± 1.77%
60 min during PCI 87.625 ± 3.20%
After 6 h 78.5 ± 7.07%
TIMI ﬂow post-PCI
Grade II 2(8.7%)
Grade III 21(91.3%)
STR
More than 70% 9(39.13%)
MBG
0–1 5(21.74%)
P2 18(78.26%)
Mean MBG± SD 2.09 ± 0.734. Results
4.1. Demographic and clinical data
The total patients in our study included 46 patients, 40 males
(87%) and six females (13%) with a mean age of 55 ± 10,
21 cases (45.7%) had diabetes mellitus, 32 cases (69.6%) had
systemic hypertension (HTN), 11 cases (23.9%) had dyslipida-
emia, 40 cases (87%) were smokers, 29 cases (63.1%) had po-
sitive family history of ischemic heart disease (IHD), 26 cases
(56.5%) had mild obesity (BMI 30–34.9 kg/m), seven cases
(15.2%) had moderate obesity [Body Mass Index (BMI) 35–
39.9 kg/m], 25 cases (54.3%) had anterior STEMI and 21 cases
(45.7%)had inferior STEMI.
Tiroﬁban group: Included 23 patients, 19 males (82.5%) and
four females (17.4%) with a mean age of 57 ± 9.65. 10 cases
(43.5%) had diabetes mellitus, 17 cases (73.9%) had systemic
hypertension, 17 cases (73.9%) had dyslipidaemia, 19 cases
(82.6%) were smokers, 18 cases (78.3%) had a positive family
history of IHD, 14 cases (60.9%) had mild obesity (BMI 30–
34.9 kg/m), ﬁve cases (21.7%) had moderate obesity (BMI
35–39.9 kg/m), 13 cases (56.5%) had anterior STEMI and 10
cases (43.5%) had inferior STEMI.
Eptiﬁbatide group: Included 23 patients, 21 males (87%)
and two females (8.7%) with a mean age of 53.48 ± 8.6. 11
cases (47.8%) had diabetes mellitus, 15 cases (65.2%) had sys-
temic hypertension, 18 cases (78.3%) had dyslipidaemia, 21n, post PCI TIMI ﬂow, STR and MBG.
Eptiﬁbatide group p value
15.71 ± 1.38% 0.8
93.5714 ± 2.07% <0.001
89.8571 ± 2.03% <0.001
1(4.3%) 1.00
22(95.7%) 1.00
15(56.22%) 0.005
0(0.0%) 0.06
23(100%) 0.53
2.87 ± 0.34 <0.001
Figure 4 ROC curve of platelet aggregation inhibition and
MBGP2 (AUC 0.81, cut-off point 87.5% with sensitivity 73.6%,
speciﬁcity 66.7%, PPV 93.9% and NPV 76.9%, p= 0.045).
246 Y.S. Nassar et al.cases (91.3%) were smokers, 11cases (47.8%) had a positive
family history of IHD, 12 cases (52.2%) had mild obesity
(BMI 30–34.9 kg/m), two cases (8.7%) had moderate obesity
(BMI 35–39.9 kg/m), nine cases (39.1%) had anterior STEMI
and 14 cases (60.9%) had inferior STEMI.
Baseline clinical characteristics were comparable in both
groups regarding age, sex and risk factors for coronary artery
disease (hypertension, diabetes mellitus, smoking, dyslipide-
mia, and a family history of ischemic heart diseases) and site
of myocardial infarction but signiﬁcant previous history of
ischemic heart diseases (p 0.033) Table. 1.
4.2. Platelet aggregation inhibition
Tiroﬁban group: The mean platelet aggregation inhibition was
15.5 ± 1.77% on admission, 87.62 ± 3.20% during PCI (60–
90 min after bolus), and 78.5 ± 7.07% 6–8 h later.
Eptiﬁbatide group: The mean platelet aggregation inhibition
was 15.71 ± 1.38% on admission, 93.57 ± 2.07% during PCI
(60–90 min after bolus), 89.85 ± 2.03% 6–8 h later Fig. 1.
Drug induced thrombocytopenia: There was no signiﬁcance
in platelet count drop (39.04 ± 34.41 versus 46.73 ± 41.48, p
0.37) in Tiroﬁban versus Eptiﬁbatide groups, respectively.
One case of Tiroﬁban group developed thrombocytopenia
(plt count dropped from 207,000 to 44,000cell/cmm within
24 h, which was complicated by cerebral hemorrhage.
4.2.1. TIMI ﬂow (post PCI)
Tiroﬁban group: TIMI ﬂow post PCI was II in two cases
(8.7%) and was III in 21 cases (91.3%).
Eptiﬁbatide group: TIMI ﬂow post PCI was II in one case
(4.3%) and was III in 22 cases (95.7%).
There was no statistical signiﬁcance between both groups
(p= 1) Fig. 2.
4.2.2. Platelet inhibition and TIMI ﬂow
Patients with TIMI ﬂow III had a mean platelet inhibition of
90.2 ± 4.6% while patients with TIMI II ﬂow had mean plate-
let inhibition of 89 ± 1.4% (p= 0.71). There was no signiﬁ-
cant statistical correlation between platelet aggregation
inhibition and TIMI ﬂow post PCI. Speciﬁcity 66.7%, PPV
93.9% and NPV 76.9% (AUC 0.81).
4.3. ST segment resolution (STR)
STRwasmore than 70% in 9(39.13%) versus 15(56.22%) patients
of Tiroﬁban versus Eptiﬁbatide groups respectively (p= 0.005).
Platelet inhibition andSTR: Patientswith STR>70%hadmean
platelet aggregation inhibitionof92.92 ± 2.49%whilepatientswith
STR<70% had mean platelet inhibition of 87.31 ± 4.15%.
There was a positive statistical correlation between platelet
inhibition and STR. the more platelet inhibition at the time of
PCI, the better STR (p 0.013, r 0.711).
The cut-off point for platelet aggregation inhibition as a
predictor of ST segment resolution >70% was 89.5% with a
sensitivity of 92.3% and a speciﬁcity of 69.2%, positive
predictive value of 75% and a negative predictive value of
10% (AUC 0.87) Fig 3.
(AUC0.87, cut-off point 89.5%, sensitivity 92.3%, speciﬁc-
ity 69.2%, PPV 75% and NPV 10%, p= 0.013).4.4. Myocardial blush grade (MBG)
MBG P2 was achieved in 23 (100%) of patients in the Eptif-
ibatide group and 18 (78.26%) of patients in the Tiroﬁban
group (p= 0.53). MBG 0–1 occurred in 5(21.74) patients of
the Tiroﬁban group and did not occur (0%) in the Eptiﬁbatide
group (p= 0.06). Mean MBG was 2.09 ± 0.73 versus
2.87 ± 0.34 in Tiroﬁban and Eptiﬁbatide groups, respectively
(p< 0.001) Table. 2.
Platelet inhibition and MBG: Patients with MBGP2 had a
mean platelet aggregation inhibition of 90.6 ± 4.42% while
patients with MBG 0–1 had a mean platelet inhibition of
86.3 ± 2.08%.
There was a signiﬁcant positive statistical correlation be-
tween platelet inhibition and MBG (p= 0.045, r= 0.453).
The cut-off point for platelet aggregation inhibition as a
predictor of MBG 2–3 was 87.5% with a sensitivity of
73.6% and a speciﬁcity of 66.7%, PPV 93.9% and NPV
76.9% (AUC 0.81) Fig. 4.
5. Complications
5.1. Bleeding complications
Total patients: Nine patients (19.6%) developed minor bleed-
ing while one patient (2.2%) developed major bleeding.
There were no site access complications (A–V ﬁstula, pseu-
doaneurysm, and major haematoma).
During 30 days follow up, there was one patient (2.2%)
with minor bleeding.
Tiroﬁban group: Five patients (21.7%) had minor bleeding
in the form of haematuria, one patient (4.3%) developed major
bleeding in the form of cerebral haemorrhge and no site access
complications. One patient (4.3%) developed haematuria and
was diagnosed to have multiple renal stones.
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bleeding in the form of haematuria and no major bleeding or
site access complications. There was no 30 day bleeding.
5.2. Catheter related complications
Coronary dissection: One patient (4.3%) of the Tiroﬁban
group developed coronary dissection of LAD proximal to
the stent so another stent was deployed with TIMI ﬂow III
with no residual stenosis. Coronary dissection did not occur
in the Eptiﬁbatide group.
Distal embolization: One patient (4.3%) of Tiroﬁban group
developed distal embolization during PCI to LAD with MBG
0–1 and unsuccessful STR. distal embolization did not occur in
the Eptiﬁbatide group.
Coronary perforation: Did not occur in any patient of the
Tiroﬁban or Eptiﬁbatide groups.
5.3. Hospital course
Length of stay: The average length of stay was
6.08 ± 2.62 days versus 5.04 ± 1.06 days, p= 0.06 in the Tir-
oﬁban versus Eptiﬁbatide groups, respectively.
Echocardiography: It was done within 72 h after PCI in total
tested patients. EF was 55.04 ± 8.5% versus 56.5 ± 6.2%
(p= 0.49) in Tiroﬁban versus Eptiﬁbatide groups, respectively.
There were no mechanical complications in any patients.
Arrhythmias:
 Complete heart block: It occurred in 2(8.7%) patients of the
Tiroﬁban group and did not occur in the Eptiﬁbatide group
(p= 0.24). CHB was transient necessitating a temporary
pacemaker and no need for a permanent pacemaker. The
culprit vessel was LAD in one case and RCA in the other
case.
 Atrial tachycardia: It occurred in the form of atrial ﬁbrilla-
tion (AF) in one(4.3%) patient of the Eptiﬁbatide group
and did not occur in the Tiroﬁban group (p= 0.317).theTable 3 Complications in Tiroﬁban and Eptiﬁbatide groups.
Tiroﬁban group
Coronary dissection 1(4.3%)
Distal embolization 1(4.3%)
Coronary perforation 0(0%)
Post infarction angina 7(30.4%)
Use of inotropes 6(26.1%)
Use of TPM 2(8.7%)
Use of PPM 0(0%)
Myocardial infarction 4(17.4%)
TVR 2(8.7%)
Death 3(13%)
Arrythmias
Heart block 2(8.7%)
Atrial tachycardia 0(0%)
Ventricular tachyacrdia 4(17.4%)
EF 55.04 ± 8.5
Hospital stay 6.08 ± 2.62
Minor bleeding 5(21.7%)
Major bleeding 1(4.3%)
30 days Bleeding 1(4.3%)
Site access complications 0(0%)culprit vessel was LAD. AF was transient without haemo-
dynamic compromise and was successfully cardioverted
with amiodarone.
 Ventricular tachycardia: Sustained VT (necessitating electri-
cal cardioversion and lidocaine infusion) occurred in
4(17.4%) patients versus 1(4.3%) patient (p= 0.08) of the
Tiroﬁban and Eptiﬁbatide groups, respectively. the culprit
vessel was LAD in 3(13%) patients versus 1(4.3%) patient
of the Tiroﬁban and Eptiﬁbatide groups, respectively and
was LCX in one patient of the Tiroﬁban group.
Postinfarction angina: It occurred in seven patients (30.4%)
of the Tiroﬁban group and only one patient (4.3%) of the
Eptiﬁbatide group (p 0.023).
5.4. Major adverse cardiac events (MACE)
Post procedural myocardial infarction: It occurred in 4(17.4%)
patients of the Tiroﬁban group and did not occur in the Eptif-
ibatide group (p= 0.12). The culprit vessel was LAD in the
four patients, one of them was associated with fatal ventricular
tachycardia/ventricular ﬁbrillation (VT/VF) while the other
two cases did coronary angiography revealing acute instant
thrombosis to which revascularization with stenting was done,
the fourth patient developed myocardial infarction after
2 weeks of PCI while doing endoscopic ureteric stone extrac-
tion with stoppage of clopidogrel and aspirin due to
haematuria.
Target vessel revascularization (TVR): It was done in
2(8.7%) patients of the Tiroﬁban group and was not needed
in the Eptiﬁbatide group (p= 0.24) Table. 3.
Death: In-hospital mortality was 2(8.7%) patients of the
Tiroﬁban group, one of them died from massive cerebral hem-
orrhage within 24 h of PCI while the other patient died from
fatal VT/VF 2 h after PCI to LAD. Three weeks after hospital
discharge, death occurred in 1(4.3%) patient versus 1(4.3%)
patient (p= 1.00) of the Tiroﬁban versus Eptiﬁbatide groups,
respectively, both cases developed sudden cardiac death atEptiﬁbatide group p value
0(0%) 0.317
0(0%) 0.317
0(0%) –
1(4.3%) 0.023
2(8.7%) 0.12
0(0%) 0.24
0(0%) –
0(0%) 0.12
0(0%) 0.24
1(4.3%) 0.34
0(0%) 0.24
1(4.3%) 0.317
1(4.3%) 0.08
56.5 ± 6.2 0.49
5.04 ± 1.06 0.06
4(17.4%) 0.5
0(0%) 0.5
0(0%) 0.5
0(0%) –
248 Y.S. Nassar et al.home within 1 h of chest pain. The patient of the Tiroﬁban
group had two vessel disease (LAD and LCX) and primary
PCI was done to LCX with unsuccessful STR while the patient
of the Eptiﬁbatide group had multivessel disease and primary
PCI was done to LAD with successful STR.
6. Discussion
Our study showed that the mean platelet aggregation inhibi-
tion by turbidometric aggregometry was signiﬁcantly less
inhibited by high dose Tiroﬁban versus Eptiﬁbatide 60 min
from the start of PCI (87.62 ± 3.2% versus 93.57 ± 2.07%,
p< 0.001) and 6 h after PCI was (78.5 ± 7.07% versus
89.85 ± 2.03%, p< 0.001) while there was not any signiﬁcant
difference on admission (15.5 ± 1.77% versus 15.7 ± 1.38%,
p 0.8) in Tiroﬁban versus Eptiﬁbatide groups, respectively.
Batchelor et al.10 in the COMPARE trial of platelet inhibi-
tion also utilizing turbidimetric aggregometry, showed that
platelet aggregation at 15 and 30 min was signiﬁcantly less
inhibited by the traditional dose (10 ug) of Tiroﬁban compared
with abciximab (p 0.028) and Eptiﬁbatide regimens (p 0.0001),
but there were no signiﬁcant differences between all GP2b3a
regimens after 4.12 and 18 h (p> 0.05). The Eptiﬁbatide reg-
imen inhibited platelet aggregation most consistently through-
out both the early and late periods, while the abciximab
regimen showed increasingly varied anti-aggregatory effects
during continued infusion for >4 h. Danzi et al.11 used the
Ultegra Rapid Platelet Function Assay, showed that platelet
inhibition was nonsigniﬁcantly different at 10 min (92 ± 6%
versus 95 ± 5%, p 0.27) then at 8 h (92 ± 6% versus
89 ± 10%, p 0.62) in the Eptiﬁbatide versus high dose
(25 ug) Tiroﬁban groups, respectively. This difference may be
due to different methods of platelet inhibition testing and
too early testing after the bolus dose without comparative
sequential timed sampling at longer time intervals.
Platelet count drop was non-signiﬁcant (39.04 ± 34.41 ver-
sus 46.73 ± 41.48, p 0.37) in Tiroﬁban versus Eptiﬁbatide
groups, respectively. This is consistent with Dasgupta et al.12
pooled analysis of eight placebo-controlled, randomized, large
trials and concluded that small-molecule GP IIb/IIIa inhibi-
tors (Tiroﬁban and Eptiﬁbatide) did not signiﬁcantly increase
mild or severe thrombocytopenia compared with placebo
and that thrombocytopenia associated with GP IIb/IIIa inhibi-
tion does not routinely lead to severe bleeding complications.
We found that post-procedural TIMI grade III was non-
signiﬁcantly different (91.3% versus 95.7%, p 1.00) in Tiroﬁ-
ban versus Eptiﬁbatide groups, respectively and TIMI ﬂow
II was observed in (8.7% versus 4.3%, p 1.00) in Tiroﬁban ver-
sus Eptiﬁbatide groups, respectively. This ﬁnding is consistent
with Abuarab et al.13 randomized trial that compared the
intracoronary double bolus of Eptiﬁbtide and high bolus dose
of Tiroﬁban as adjuncts to primary PCI in patients with ante-
rior STEMI and concluded that there was no signiﬁcant differ-
ence in post procedural TIMI III ﬂow in both groups. De Luca
et al.14 meta-analysis of six randomized trials concluded that
there was no signiﬁcant difference in post-procedural TIMI
ﬂow grade III (89.8% versus 89.1%, p 0.72) in abciximab ver-
sus Eptiﬁbatide and Tiroﬁban, respectively.
Successful ST segment resolution (STR) more than 70%
was found to be signiﬁcantly lower with high dose Tiroﬁban
that Eptiﬁbatide (39.13% versus 56.22%, p 0.005) in Tiroﬁbanversus Eptiﬁbatide groups, respectively. Patients with success-
ful STR had a mean platelet aggregation inhibition of
92.2 ± 3.5% while patients with unsuccessful STR had a mean
platelet inhibition of 85.5 ± 2.2%. This was supported by a
signiﬁcant positive statistical correlation between platelet inhi-
bition and STR (p 0.013, r 0.71).
The cut-off point for platelet aggregation inhibition as a
predictor of STR >70% was 89.5% (sensitivity 92.3%, speci-
ﬁcity 69.2%, PPV 75% and NPV 10%, AUC 0.87). Abuarab
et al.13 also concluded that in anterior infarction, successful
ST segment resolution (70.9 ± 11.3 versus 59.7 ± 9,
p< 0.001) in intracoronary Eptiﬁbatide versus Tiroﬁban,
respectively. Marzocchi et al.16 in the facilitated angioplasty
with Tiroﬁban or Abciximb (FATA) trial failed to show the
equivalence of high bolus dose of Tiroﬁban and abciximab
regarding complete STR (67.05% versus 70.45%, p< 0.05)
as adjunctive therapy to primary PCI. Zeymer et al.15 in the
EVA-AMI randomized controlled multicenter concluded that
Eptiﬁbatide is equally effective as abciximab with respect to
STR in patients with STEMI.
The mean myocardial blush grade (MBG) was (2.09 ± 0.73
versus 2.87 ± 0.34, p< 0.001) in the Tiroﬁban and Eptiﬁba-
tide groups, respectively. There was a positive correlation be-
tween platelet inhibition and MBG (p 0.045, r 0.453).The
cut-off point for platelet aggregation inhibition as a predictor
of MBG 2–3 was 87.5% (sensitivity 73.6%, speciﬁcity 66.7%,
PPV 93.9% and NPV 76.9%, AUC 0.81).
Abuarab et al.13 similarly concluded that MBG II and III
indicating successful reperfusion was achieved in 76.6% versus
36.6%, (p 0.005) in intracoronary Eptiﬁbatide versus high dose
Tiroﬁban group, respectively.
In our study, STR and MBG P2 were concordant with
each other as markers of myocardial reperfusion. De Luca
et al.18 used STR and MBG (concordant relation) to assess
myocardial perfusion in patients with STEMI after primary
PCI. Haager et al.19 evaluated myocardial blush grade 0–1
(p= 0.033) and persistent ST segment elevation (p= 0.017)
as independent predictors for long-term mortality after angio-
plasty in AMI. Sorajja et al.17assessed the 30 days and 1 year
clinical outcomes of 456 patients using STR >70% and
MBG after primary PCI and concluded that both STR and
MBG are measures of reperfusion success that strongly corre-
late with survival and assessment of both yields greater prog-
nostic information than either one alone. Since MBG reﬂects
microvascular patency facilitating myocardial reperfusion
while STR reﬂects cellular integrity and the dynamic and
evolving changes after myocardial reperfusion, the two param-
eters may not necessarily be concordant.
Our monitoring for complications showed that minor
bleeding, in the form of haematuria, occurred (21.7% versus
17.4%, p 0.5) in Tiroﬁban versus Eptiﬁbatide groups, respec-
tively. Major bleeding, in the form of cerebral hemorrhage
occured (one patient 4.3% versus 0, p 0.5) in Tiroﬁban ver-
sus Eptiﬁbatide groups, respectively. Thirty days bleeding
occurred in (4.3% versus 0, p 0.5) in Tiroﬁban versus Eptif-
ibatide groups, respectively which was in form of minor
bleeding (haematuria) and the patient was diagnosed to have
renal stones. There were no site access complications in both
groups.
De Luca et al.24 meta-analysis of six randomized trials com-
paring abciximab versus small molecules (Eptiﬁbatide and Tir-
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difference in major bleeding complications (1.3% versus
1.9%, p 0.27). Casterella et al.20 studied 4321 patients undergo-
ing PCI and received a single GP IIb/IIIa inhibitor (abciximab,
1178; Eptiﬁbatide, 1698; Tiroﬁban, 1445). Major bleeding
complications were rare, ranging from 1.9% to 3.1%, and
transfusion rates were low, ranging from 0.8% to 2.1%, with
no signiﬁcant differences among the agents evaluated.
We found no signiﬁcant differences between Tiroﬁban
and Eptiﬁbatide groups regarding procedure related compli-
cations (coronary dissection, distal embolization and coro-
nary perforation), length of hospital stay, post procedure
echocardiography and arrhythmias. There was signiﬁcant
statistical difference between both groups regarding postin-
farction angina (4.3% versus 30.4%, p 0.023) in Eptiﬁbatide
versus Tiroﬁban groups, respectively. Our results were simi-
lar to those of Abuarab et al.13 that showed recurrent ische-
mia (0% versus 16.7%, p 0.026) in Eptiﬁbatide versus
Tiroﬁban groups, respectively. There was no statistically sig-
niﬁcant difference between the two groups regarding total
MACE. Thirty days mortality was 3(13%) versus 1(4.3%)
(p 0.34) of Tiroﬁban versus Eptiﬁbatide groups, respectively.
Post-procedural myocardial infarction occurred in four pa-
tients (17.4%) of the Tiroﬁban group and did not occur in
the Eptiﬁbatide group (p 0.12). Target vessel revasculariza-
tion (TVR) was done in two patients (8.7%) of the Tiroﬁ-
ban group while it was not needed (0%) in the
Eptiﬁbatide group (p 0.24). Abuarab et al.13 concluded that
there was no signiﬁcant difference in the rate of in-hospital
MACE among both groups with one death (3.3%) in each
group, but recurrent ischemia was higher in the Tiroﬁban
group (0% versus 16.7%, p 0.026) in intracoronary Eptiﬁba-
tide versus Tiroﬁban groups, respectively. Casterella et al.20
showed that there were no signiﬁcant differences in 1-year
mortality, myocardial infarction, and urgent target vessel
revascularization was identiﬁed among abciximab, Eptiﬁba-
tide and Tiroﬁban. Zeymer et al.15 in EVA-AMI randomized
controlled trial showed that mortality was (6.2% versus
4.5%, p 0.5), reinfarction (0.4% versus 3.5%, p 0.03),
TVR (4.4% versus 6.5%, p 0.4), stroke (0.5% versus
0.5%, p 1.00) after 6 months of Eptiﬁbatide and abciximab,
respectively and concluded that Eptiﬁbatide is equally effec-
tive as abciximab in patients with STEMI. Gum et al.21
evaluated the outcomes of 3541 patients who underwent pri-
mary PCI for STEMI and concluded that there was no dif-
ference in the incidence of in-hospital death (4.1% versus.
3.5%, p 0.39), recurrent myocardial infarction (0.8% versus.
1.2%, p 0.42), or stroke/transient ischemic attack (0.7% ver-
sus. 0.6%, p 0.80) in abciximab versus Eptiﬁbatide patients
respectively, so that the study concluded that there was no
apparent difference in early outcomes of patients treated
with Eptiﬁbatide compared with patients treated with abcix-
imab. Another comparative multicenter study by Akerblom
et al.22 compared all (n= 11.479) STEMI patients, in Swe-
den who underwent primary PCI and concluded that Eptif-
ibatide is noninferior to abciximab with respect to death or
myocardial infarction during one year. Our results together
with the other previous studies all support that there are
no signiﬁcant differences regarding the complication rates
between different regimens of GP2b3a antagonists used in
primary PCI of patients with STEMI.6.1. Limitations of the study
The small sample size of the study. The evidence of myocardial
reperfusion could have been supported by myocardial scintigraphic
imaging. The absence of long term follow up since the beneﬁcial ef-
fects observed in terms of epicardial recanalization and myocardial
perfusion may be translated into beneﬁts in terms of left ventricular
remodeling and larger survival beneﬁts at long term.7. Conclusions
 Eptiﬁbatide achieves better platelet aggregation inhibition
60 min after bolus and 6 h after PCI than high dose
Tiroﬁban.
 Eptiﬁbatide is associated with better myocardial perfusion
as indicated by post procedural mean MBG and STR
>70% than high dose Tiroﬁban.
 Platelet aggregation inhibition during PCI was signiﬁcantly
correlated with STR and MBG. Platelet aggregation inhibi-
tion cut-off point as a predictor of STR >70% was 89.5%,
and as a predictor of MBG 2–3 was 87.5%.
 There were no signiﬁcant differences between Eptiﬁbatide
and Tiroﬁban regarding thrombocytopenia, major or minor
bleeding, MACE and 30 days mortality.
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